05/15/21
WorkersCompensation.com
WALNUT CREEK, CA May 6, 2021 Paradigm, the industry leader in solving catastrophic and complex health care challenges and improving lives, today announced the appointment of two individuals to newly created executive leadership positions. Joining the organization are Tom Mafale as Chief Growth Officer and Jason Cooper as Chief Data and Analytics Officer. The addition of these two senior leadership roles represents an essential step in Paradigm s vision for strategic growth with a reliance on robust data-based practices.
“With Tom and Jason, we are fortunate to have found experienced executives for these critical new roles. Both leaders backgrounds and values closely align with Paradigm s deep clinical expertise and mission to change lives,” said John Watts, Chief Executive Officer of Paradigm. “I m looking forward to working closely with both Tom and Jason on key strategic initiatives that amplify Paradigm s impact on the people we serv
Paradigm Appoints Two Key Executive Leaders for Continued Strategic Growth
News provided by
Share this article
Share this article
WALNUT CREEK, Calif., May 6, 2021 /PRNewswire/ Paradigm, the industry leader in solving catastrophic and complex health care challenges and improving lives, today announced the appointment of two individuals to newly created executive leadership positions. Joining the organization are Tom Mafale as Chief Growth Officer and Jason Cooper as Chief Data and Analytics Officer. The addition of these two senior leadership roles represents an essential step in Paradigm s vision for strategic growth with a reliance on robust data-based practices. With Tom and Jason, we are fortunate to have found experienced executives for these critical new roles. Both leaders backgrounds and values closely align with Paradigm s deep clinical expertise and mission to change lives, said John Watts, Chief Executive Officer of Paradigm. I m looking forward to working c
Read later
Summary:
A new FTC mandate is intended to crack down on AI abuses. How will it work? Are crucial areas of AI abuse overlooked? Here s my first cut analysis.
On April 19, 2021, in a blog titled, Aiming for truth, fairness, and equity in your company s use of AI, Elisa Jillson of the FTC, in an atypical fashion, put U.S. organizations on notice that the FTC would use its various powers to investigate AI abuses, and presumably take action:
Hold yourself accountable - or be ready for the FTC to do it for you.
Let s first examine the breadth of the FTC s mandate for enforcement:
The U.S. Federal Trade Commission emphasized the importance of using artificial intelligence in an equitable manner in a blog post earlier this month.
As FTC attorney Elisa Jillson noted in the post, so-called neutral technology can produce troubling outcomes, including racial discrimination or the replication of other biases. As your company launches into the new world of artificial intelligence, keep your practices grounded in established FTC consumer protection principles, Jillson advised.
WHY IT MATTERS
AI has the potential to advance innovation in the healthcare industry. But, as Jillson (and others) points out, tools are only as unbiased as the data they re trained on – and too often, that data represents the bias of its creators.
MedCity News
Precision medicine can close care gaps to reduce incidence of cancer
As researchers and clinicians understand and embrace the advanced insights genetic and genomic testing can deliver, the industry is poised to dramatically reduce the incidence and mortality associated with cancers.
Shares0
Cancer is the second leading cause of death in the U.S., according to the Center for Disease Prevention and Control (CDC), behind heart disease. Within the universe of cancers, breast is the most common, followed by lung, prostate and colorectal, according to the National Cancer Institute (NCI).
Treatment costs have skyrocketed. According to one report published by The Mesothelioma Center, the burden of cancer care in the U.S. topped $150 billion in 2018, four times higher than treatment for other conditions. The most expensive forms of cancer are lung, colorectal, breast and mesothelioma.